Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis.
10.3779/j.issn.1009-3419.2021.102.27
- Author:
Yunwei LIU
1
;
Yanxin CHEN
1
;
Zhimin ZENG
1
;
Anwen LIU
1
Author Information
1. Department of Oncology, The Second Affiliated Hospital of Nanchang University,
Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang 330006, China.
- Publication Type:Journal Article
- Keywords:
Cardiotoxicity;
Immune checkpoint inhibitor;
Myocarditis
- MeSH:
Biomedical Research/trends*;
Cardiotoxicity/physiopathology*;
Humans;
Immune Checkpoint Inhibitors/therapeutic use*;
Immunotherapy/adverse effects*;
Myocarditis/physiopathology*;
Neoplasms/drug therapy*
- From:
Chinese Journal of Lung Cancer
2021;24(9):668-672
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions.
.
